Seco-Hidalgo, Victor
Witney, Adam A.
Chico, Martha E.
Vaca, Maritza
Arevalo, Andrea
Schuyler, Alexander J.
Platts-Mills, Thomas A. E.
Ster, Irina Chis
Cooper, Philip J.
Funding for this research was provided by:
National Institutes of Health (RO1-AI-20565)
Wellcome Trust (088862/Z/09/Z)
Article History
Received: 30 October 2024
Accepted: 4 February 2025
First Online: 15 February 2025
Change Date: 1 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-025-95200-w
Declarations
:
: The authors declare no competing interests.
: All human subjects research was performed in accordance with local regulations of the Ecuadorian Ministry of Public Health and the Declaration of Helsinki. The study protocol was approved by the ethics committees of the Hospital Pedro Vicente Maldonado (2005) and Universidad San Francisco de Quito (2010). Informed written consent was obtained from the child’s mother or legal guardian for collection of clinical samples and data. Anti-protozoal treatments (metronidazole or tinidazole) were offered to symptomatic children with E. histolytica or G. lamblia trophozoites in fresh stool samples. Individuals with positive stools for soil-transmitted helminth infections were treated with a single dose of albendazole if aged 2 years or greater and with pyrantel pamoate if aged < 2 years, according to Ecuadorian Ministry of Public Health recommendations106.